Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-21
2009-08-04
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000
Reexamination Certificate
active
07569547
ABSTRACT:
Small, polybasic peptides are disclosed that are effective as furin inhibitors, e.g. hexa- to nona-peptides having L-Arg or L-Lys in most positions. Removing the peptide terminating groups can improve inhibition of furin. High inhibition was seen in a series of non-amidated and non-acetylated polyarginines. The most potent inhibitor identified to date, nona-L-arginine, had a Kiagainst furin of 40 nM. Non-acetylated, poly-D-arginine-derived molecules are preferred furin inhibitors for therapeutic uses, such as inhibiting certain bacterial infections, viral infections, and cancers. Due to their relatively small size, these peptides should be non-immunogenic. These peptides are efficiently transported across cell membranes.
REFERENCES:
patent: WO92/07871 (1992-05-01), None
patent: WO 97/18826 (1997-05-01), None
patent: WO 01/66127 (2001-09-01), None
patent: WO 01/83554 (2001-11-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320.
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Johnson et al, Cancer Treatment Reviews, vol. 2 p. 1 (1975).
Bae et al JBC vol. 275 p. 13588 (May 2000).
Angliker, H., “Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin,”J. Med. Chem., vol. 38, pp. 4014-4018 (1995).
Basak, A. et al.,Int. J. Pept. Protein Res., vol. 44, pp. 253-261 (1994) (Abstract).
Basak, a. et al., “Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters,”Biochem. J. 338, pp. 107-113 (1999).
Cameron, A. et al., “Polyarginines are potent furin inhibitors,”J. Biol. Chem. . . vol. 275, pp. 36741-36749 (2000).
Coyle, A. et al., “Role of Cationic Proteins in the Airway,”Am. J. Respir. Crit. Care Med., vol. 150, pp. S63-S71 (1994).
Frigas, E. et al., “Elevated Levels of the eosinophil Granule Major Basic Protein in the Sputum of Patients with Bronchial Asthma,”Mayo Clin. Proc., vol. 56, pp. 345-353 (1981).
Gordon et al., “Proteolytic Activation of Bacterial Toxins: Role of Bacterial and Host Cell Proteases,” Infect. Immun. vol. 62, pp. 333-340 (1994).
Gudmundsson, S. et al., “Murine thigh infection model,” in O. Zak et al. (Eds.),Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy, pp. 137-144 (1999).
Hallenberger, S. et al., “Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein GP160,”Nature, vol. 360, pp. 358-361 (1992).
Jean, J. et al., “α1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: Application as an antipathogenic agent,”Proc. Natl. Acad. Sci. USA, vol. 95, pp. 7293-7298 (1998).
Johansen, H. et al., “Rat model of chronicPseudomonas aeruginosalung infection,” in O. Zak et al. (Eds.),Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy, pp. 517-526 (1999).
Ko, K. et al.,Am. J. Physiol., vol. 277, pp. L811-L815 (1999).
Komiyama, T. et al., “Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin,”Biochem., vol. 39, pp. 15156-15165 (2000).
Krysan, D. et al.,J. Biol. Chem., vol. 274, pp. 23229-23234 (1999).
Lu, W. et al., “Arg15-Lys17-Arg18turkey ovomucoid third domain inhibits human furin,”J. Biol. Chem., vol. 268, pp. 14583-14585 (1993).
Mitchell, D. et al., “Polyarginine enters cells more efficiently than other polycationic homopolymers,”J. Peptide Res., vol. 56, pp. 318-325 (2000).
Molloy, S. et al., “Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis,”Trends in Cell Biology, vol. 9, pp. 28-35 (1999).
Peinado, Juan R. et al., “Cross-Inhibition Between Furin and Lethal Factor Inhibitors,” Biochemical and Biophysical Research Communications, vol. 321, pp. 601-605 (2004).
Sarac, Miroslav et al., “Protection Against Anthrax Toxemia by Hexa-D-Arginine in Vitro and in Vivo,” Infection and Immunity, vol. 72, pp. 602-605 (2004).
Sarac, Miroslav et al., “The Furin Inhibitor Hexa-D-Arginine Blocks the Activation ofPseudomonas aeruginosaExotoxin A.In Vivo,” Infection and Immunity, vol. 70, No. 12, pp. 7136-7139 (2002).
Shinde, U. et al.,Semin. Cell Dev. Biol., vol. 11, pp. 35-44 (2000);.
Vepa, S. et al.,Am. J. Physiol., “Activation of endothelial cell phospholipase D by polycations,” vol. 272, pp. L608-L613 (1997).
Zhong, M. et al.,J. Biol. Chem., vol. 274, pp. 33913-33920 (1999).
Appel Jon Richard
Cameron Angus
Houghten Richard A.
Lindberg Iris
Board of Supervisors of Louisiana State University and Agricultu
Davis Bonnie J.
Huff Sheela J
Runnels John H.
Torrey Pines Institute for Molecular Studies
LandOfFree
Inhibiting furin with polybasic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting furin with polybasic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting furin with polybasic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130389